Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1000

—

701d2450-e03c-59fb-927f-f3aa4972e5c0

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MYC_TARGETS_V2+0.649
  • MYC_TARGETS_V1+0.512
  • E2F_TARGETS+0.482
  • G2M_CHECKPOINT+0.471
  • UNFOLDED_PROTEIN_RESPONSE+0.429
  • MITOTIC_SPINDLE+0.369
  • DNA_REPAIR+0.352
  • MTORC1_SIGNALING+0.222
  • TGF_BETA_SIGNALING+0.178
  • HEDGEHOG_SIGNALING+0.175

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.489
  • INTERFERON_GAMMA_RESPONSE-0.464
  • ALLOGRAFT_REJECTION-0.431
  • IL6_JAK_STAT3_SIGNALING-0.360
  • INFLAMMATORY_RESPONSE-0.357
  • COMPLEMENT-0.332
  • TNFA_SIGNALING_VIA_NFKB-0.318
  • APICAL_SURFACE-0.301
  • KRAS_SIGNALING_UP-0.276
  • COAGULATION-0.265

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG365
mng-umap@100
——0.919
2b1802901-fe29-4665-b960-ca263cba9243
melanoma-umap@29
——0.917
3MNG1194
mng-umap@100
——0.912
4CA366342-0949-4941-8AE6-984BAF032886
brain-umap@2
——0.895
5TCGA-A8-A07L-01A-11R-A00Z-07
breast-umap@18
—B0.891
6C6A16A8F-0AB7-42E9-A068-15EECF2912D3
brain-umap@2
——0.887
7TCGA-50-5931-01A-11R-1755-07
lung-landscapes@6
—cohortMD10.885
8SRR25043616
head-neck@1
——0.883
9MDT-AP-0167
medullo-epn-umap@date-based
MedMedulloblastoma0.879
10SRR6013533
lung-landscapes@6
—cohortSQ20.878

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MYC_TARGETS_V20.649Idelalisib— uncovered
MYC_TARGETS_V10.512Inavolisib— uncovered
E2F_TARGETS0.482Inavolisib— uncovered
G2M_CHECKPOINT0.471Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.429Idelalisib— uncovered
MITOTIC_SPINDLE0.369Inavolisib— uncovered
DNA_REPAIR0.352Idelalisib— uncovered
MTORC1_SIGNALING0.222Inavolisib— uncovered
TGF_BETA_SIGNALING0.178Inavolisib— uncovered
HEDGEHOG_SIGNALING0.175Inavolisib— uncovered
PROTEIN_SECRETION0.172Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.158Inavolisib— uncovered
GLYCOLYSIS0.149Inavolisib— uncovered
NOTCH_SIGNALING0.133Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.124Remibrutinib— uncovered
UV_RESPONSE_DN0.109Inavolisib— uncovered
ADIPOGENESIS0.067Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.067Inavolisib— uncovered
APICAL_JUNCTION0.046Inavolisib— uncovered
UV_RESPONSE_UP0.041Idelalisib— uncovered